Abstract: Among the various aspects of the present disclosure is the provision of methods, synthetic DC, and compositions for T cell activation. The present disclosure provides for synthetic dendritic cells (DCs), methods of generating synthetic dendritic cells (DCs), methods of generating T cell-encapsulated gelatin microspheres and microcapsules, methods of activating T cells using synthetic DCs, methods for expanding T cells against individualized antigen-specific mutational antigens using synthetic DCs, and methods of treating a chronic disease (e.g., HIV, HPV) or cancer using the synthetic DCs.

Abstract: The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.

Abstract: Among the various aspects of the present disclosure is the provision of methods, synthetic DC, and compositions for T cell activation. The present disclosure provides for synthetic dendritic cells (DCs), methods of generating synthetic dendritic cells (DCs), methods of generating T cell-encapsulated gelatin microspheres and microcapsules, methods of activating T cells using synthetic DCs, methods for expanding T cells against individualized antigen-specific mutational antigens using synthetic DCs, and methods of treating a chronic disease (e.g., HIV, HPV) or cancer using the synthetic DCs.

Abstract: The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.

Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.

Abstract: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: Cyclic beta glucan compounds function as an immunoadjuvant when administered prior to, concommitantly with, or subsequent to the administration of one or more antigens to a subject. These adjuvant compounds may be effectively used as dendritic cell activating molecules.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: The present invention relates to a cyclic beta glucan compound for use as an immuno adjuvant and vaccine composition comprising thereof. These novel adjuvant compounds represent in particular a new class of dendritic cell activating molecules.

Abstract: Compositions and methods for inhibiting effector CD8+ T cell priming by Langerhans cells (LCs), together with promotion of the production of IL-4 and IL-10 are disclosed herein. The findings of the present indicate that immunoglobulin-like transcript (ILT) inhibitory receptors expressed on dermal CD14+ DCs represent natural counterparts of the anti-CD8 mAbs. Accordingly, blocking ILT2 or ILT4 on dermal CD14+ DCs enhanced the generation of effector polyfunctional CD8+ T cells. Conversely, soluble ILT2 and ILT4 act as CD8-antagonists that inhibit effector CD8+ T cell priming by LCs, together with promoting the production of IL-4 and IL-10. The results presented herein indicate that ILT receptor family members can skew the polarization of CD8+ T cell responses and strategies to block ILT expression on dendritic cells (DCs) may be useful to augment dendritic cell function to enhance responses to cancer or chronic viral infections.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract: Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming.

Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.

Abstract: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.